#United States #San Francisco #OmicsBank #ClinicalData #HealthAI

OmicsBank Secures $2.25 Million to Expand Global Clinical Data Infrastructure

Overview
In a timely move aimed at revolutionizing healthcare data systems, OmicsBank has announced a substantial seed funding round amounting to $2.25 million. This funding, sourced from global venture capital firm Redesign Health, is set to enhance the company’s mission of connecting fragmented clinical data within hospitals. As a company at the intersection of healthcare, life sciences, and AI, OmicsBank is poised for significant growth.

The Urgent Need for Diverse Data
The efficacy of drug development and healthcare AI relies on comprehensive datasets, which are currently skewed heavily towards the U.S. and European demographics. This underrepresentation is critical, particularly considering that countries like India and those in South Asia, which collectively comprise a significant portion of the world’s population, only contribute to a mere 2% of large-scale genomic research. Such gaps highlight a pressing need for more inclusive datasets in order to foster innovation and finding in healthcare.

OmicsBank’s infrastructure aims to close this gap by establishing a robust network that gathers clinical and genomic information from diverse populations, particularly those in Asia and the Middle East. This initiative is vital for creating equitable healthcare solutions that can serve global populations effectively.

Building the Infrastructure
Founded in 2025 by Sumit Sinha and Vijay Goel, OmicsBank has made strides in establishing itself within the healthcare landscape. The company has successfully integrated its technology into over 90 hospitals across Asia, working to standardize and de-identify multimodal data directly at the source. This remarkable infrastructure encompasses vital records, including longitudinal electronic health records from 12.5 million patients, over 30 million DICOM images, and 500,000 genome sequences.

OmicsBank's work spans multiple medical disciplines, collaborating with pharmaceutical and biotechnology firms on drug development and real-world evidence studies in fields such as oncology, neurology, and endocrinology. Their partnerships with frontier AI organizations emphasize their commitment to enhancing clinical models through advanced machine learning techniques.

Global Expansion Plans
The recent funding will enable OmicsBank to extend its reach into the U.S. market, thereby facilitating connections between Asian clinical data and American healthcare systems. This two-pronged approach not only aids in establishing partnerships within the U.S. but also allows for a diverse research-ready data pool from Asia, benefiting pharmaceutical and biotechnology research groups.

As OmicsBank expands its network, it addresses the broader challenge of fragmented hospital data. By linking clinical events with imaging and multi-omics data, they create thoroughly comprehensive datasets that empower institutions to conduct research and develop new treatments. Participating hospitals will also significantly benefit by having tools that enable them to query their clinical archives and identify relevant research cohorts.

Insights from Industry Leaders
Industry experts recognize the value OmicsBank brings to healthcare innovation. Neil Patel, Head of Ventures at Redesign Health, emphasized that breakthrough solutions often arise from founders who understand the intricacies of both local and global healthcare challenges. The founders of OmicsBank, having built multiple successful firms, possess the operational expertise required to navigate these complexities effectively.

Oscar Ramos Moreno, Managing General Partner at Orbit Ventures, underscored the critical need for medical research that reflects the populations that are often overlooked. He stated, "OmicsBank is committed to ensuring that these global populations contribute to healthcare outcomes by making their data accessible and impactful."

Future Directions
With the funding in place, OmicsBank will not only grow its hospital network but will also enhance its relationships with pharmaceutical and biotechnology firms. Furthermore, the company plans to develop advanced GPU-enabled research environments, enhancing capabilities in model training, biomarker discovery, and real-world evidence studies, thus fostering innovation in computational biology.

About OmicsBank
OmicsBank stands as a trailblazer in clinical data infrastructure, transforming unstructured clinical records into standardized datasets essential for research and AI applications. The company is compliant with international regulations, offering a broad spectrum of healthcare data, including EHR, imaging, and genomic metrics. Backed by notable venture capital firms, OmicsBank is headquartered in San Francisco, California, and continues to drive progress in healthcare data accessibility and usability.